Curis And Autolus Rise On EHA Abstract Data
Potential Advances In AML and NHL
Promising early-stage data from two companies looking to break into crowded hemato-oncology markets.
You may also be interested in...
Autolus, Scholar Rock, Rocket and Pfizer have managed to convince the European Medicines Agency that their investigational treatments merit a place on the regulator’s priory medicines scheme.
SNG001 has moved into a Phase III open label trial in which it must prove its non-inferiority against Regeneron's monoclonal antibody cocktail.
The King's College London spin-out has gained £11.5m backing to take its ‘parallel CAR-T’ into the clinic.